Exelixis
Merck gets a leg-up for Keytruda in first-line kidney cancer
Phil Taylor
Bristol-Myers Squibb, Cabometyx, Eisai, Exelixis, immuno-oncology, Inlyta, Keytruda, Lenvima, Merck & Co, Oncology, Opdivo, Pfizer, renal cell carcinoma, Sutent, Yervoy
0 Comment
Exelixis takes $20m option Iconic/Zymeworks’ cancer ADC
Richard Staines
cancer, Exelixis, Iconic Therapeutics, Zymeworks
0 Comment
FDA kicks off review of second kidney cancer combo based on BMS’ Opdivo
Phil Taylor
Bristol-Myers Squibb, Cabometyx, Exelixis, immuno-oncology, Oncology, Opdivo, renal cell carcinoma
0 Comment
News/ News/ Oncology/ Top stories
Exelixis doubles down on ADCs for cancer with NBE, Catalent deals
Phil Taylor
antibody-drug conjugate, Catalent, Exelixis, licensing, NBE-Therapeutics, Oncology
0 Comment
BMS gets an important win for Opdivo combination in kidney cancer
Phil Taylor
Bristol-Myers Squibb, Exelixis, immuno-oncology, kidney cancer, Merck & Co, Oncology, Opdivo, Pfizer, renal cell carcinoma
0 Comment
Ipsen/Exelixis’ drug approved in EU for kidney cancer
Richard Staines
Exelixis, Ipsen, kidney cancer, renal cell carcinoma
0 Comment
Cabometyx secures new indication in renal cell carcinoma.